Du är här

2014-04-30

Vida Cannabis Corp. : Vida Cannabis Corp. Appoints Pritesh Kumar Chief Cannabinoid Research Scientist and Quality Assurance Officer of Vida Cannabis (Canada)

Toronto, Ontario - April 30, 2014 - Vida Cannabis Corp.
("Vida Cannabis") is pleased to announce the appointment of Pritesh Kumar as
the Company's Chief Cannabinoid Research Scientist as well as Quality
Assurance Manager of its wholly owned subsidiary, Vida Cannabis (Canada) Ltd.
("Vida Canada").

Pritesh Kumar, M.S. Pharmacology, is a cannabinoid research scientist and
consultant trained in ensuring Quality Assurance/Quality Control (QA/QC),
current Good Manufacturing Practices (cGMP), current Good Production
Practices (GPP) and current Good Laboratory Practices (cGLP) of
pharmaceutical products and Active Pharmaceutical Ingredients (APIs). As
Cannabinoid Pharmacologist and Laboratory Manager since 2009, Pritesh has
conducted medical cannabinoid research as it pertains to the cannabinoid
receptor 2 (CB2), pharmacological testing of FDA approved drugs as potential
ligands for CB2, investigated the pharmacology of cannabidiol (CBD) for CB2
and been responsible for all aspects of managing the laboratory as well as QA
as it pertains to sampling, handling and testing of cannabinoid drugs.
Previously, Mr. Kumar served as a Research Assistant with the Department of
Nutritional Biochemistry at the University of Kentucky and Quality Control
Analyst for Heartland Sweeteners&Lexington Pharmaceuticals.

Mr. Kumar is skilled in medical pharmacology, HPLC and GC/MS, especially as
applied toMarihuana for Medical Purposes Regulations
(MMPR), HIPAA, PHIA, FDA regulations, ISO standards (ISO 17025, ISO 15189 and
ISO 9001) and cannabis policy development and legislative documentation. His
areas of specialty include QA of cannabinoids, nutritional biochemistry,
molecular biology, pharmaceuticals and purification.

He has extensive experience preparing documentation pertaining to medical
marijuana license acquisition in both Canada and the United States and
advises clients on issues regarding proper laboratory equipment for cannabis
testing, pharmacology of cannabis-based therapeutics and maintaining a QA
system to ensure compliance. He is also the Scientific Adviser to Kentucky
Senator Perry Clark and advises on issues regarding the development of
effective medical cannabis policies and preparation/ implementation of
legislative bills to ensure the implementation of a proper QA system.

Pritesh Kumar's award-winning study, which he presented at the International
Cannabinoid Research Society in 2013 in Vancouver, focused on the
identification of raloxifene as a novel CB2 inverse agonist. His current
research focuses on the integration of computer modeling and pharmacological
testing of components to identify novel leads for the G protein-coupled
cannabinoid receptors CB1 and CB2, which have been shown to regulate a broad
spectrum of physiological conditions from regulating appetite to pain.

Pritesh Kumar received a Master's of Science in Pharmacology, Cannabinoid
Concentration, from the University of Louisville in 2011 and is currently
completing a Ph.D. in Pharmacology, Cannabinoid Concentration, expected in
2014. He earned a Bachelor's of Science in Biology from the University of
Kentucky. He is a Fellow with the National Institute of Environmental Health
Sciences and has received honors and awards including Best Oral Presentation
from the International Cannabinoid Research Society (ICRS) Conference in
Vancouver and fellowships from Drug Discovery and Target in Boston and
Integrated Programs in Biomedical Sciences (IPIBS) as well as travel awards
from the National Institute on Drug Abuse and University of Louisville School
of Medicine for his presentations in Vancouver, Freiburg, Pennsylvania and
Illinois.

Mr. Kumar has been published in numerous scientific journals including
theEuropean Journal of Pharmacology, Pharmacology and Physiology, Journal of
Medicinal Chemistry, Investigative Ophthalmology&Visual Science and
Biochemical and Biophysical Research Communications
. He is an active member of the International Association for Cannabis as
Medicine (IACM), National Cannabis Industry Association (NCIA) and Liaison
Committee on Medical Education (LCME) of the University of Louisville School
of Medicine. In addition, Mr. Kumar is a member of the International
Cannabinoid Research Society (ICRS), American Society of Cell Biology (ASCB)
and National Glaucoma Society (NGS) and was a member of the University of
Louisville's Technology Sub-committee.

Vida Cannabis CEO Greg Wilson stated: "I am delighted to welcome Pritesh Kumar
to the Vida team. His research focus on cannabinoid pharmacology and
experience managing laboratories combined with his extensive quality control
skill set result in an ideal match for Vida's needs. We are particularly
excited to have Pritesh oversee, on behalf of Vida Cannabis, the development
of customized strains of medical marijuana to meet our customers' health
needs including, we expect, proprietary Vida Cannabis strains. And because of
his extensive familiarity with the relatively new MMPR, he has contributed
valuable insight in the final steps of our licensing application process and
is ideally suited to participate in a strong, ongoing relationship between
Vida Canada and Health Canada."

About Vida Cannabis Corp.

Vida Cannabis Corp. ("Vida Cannabis") is focused on developing a dominant
production footprint in the rapidly developing global marketplace for the
legal use of medicinal and recreational marijuana.

Initial operations are focused on the Canadian market where Health Canada has
established national guidelines enabling best-in-class producers to acquire
commercial production licenses under theMarihuana for Medical Purposes
Regulations
.

Via its wholly owned subsidiary, Vida Cannabis (Canada) Ltd., Vida Cannabis
purchased a 315,000-square-foot production facility in the town of
Stellarton, NS and secured a 50-year irrevocable approval unanimously from
the local municipality to operate a medical marijuana production plant at the
facility.

The highly secure facility boasts a fully engineered concrete floor,
18-foot-high concrete walls and a steel roof making it an ideal location for
the construction of a customized, state-of-the-art modern medical marijuana
production plant.

Vida Cannabis is working with one of the most talented cannabis consulting
teams in the world, Quantum 9 Inc., which has extensive resources in the
United States, Canada and Europe, to establish an optimized end-to-end
production plan to help position Vida Cannabis with the largest, most
advanced medical marijuana facility in Canada.

Vida Cannabis continues to evaluate additional potential markets as regulatory
bodies around the world pass legislation enabling the production and
distribution of medicinal or recreational marijuana.

On behalf of the board,

Greg Wilson - Chairman&CEO

Vida Cannabis Corp.

Investor Services

Toll free +1 800 593 1585

Direct: +1 647 560 4482

Email:InvestorServices@VidaCannabis.com

Web:VidaCannabis.com

Disclaimer

This announcement does not constitute or form part of, and shall under no
circumstances be considered as, an offer to sell, a solicitation to purchase,
or advice on investments in any securities of Vida Cannabis Corp. ("Vida
Cannabis"). Offers and solicitations shall be expressly identified as such
and made in compliance with applicable securities laws. This announcement is
for information purposes only. It should not be relied upon as a basis for
investment decisions. You should consult with your own investment,
accounting, legal and tax advisers to evaluate independently the risks,
consequences and suitability of any investments you are considering. Whilst
the information provided here is believed to be reliable, it cannot be
guaranteed. It may contain forward-looking statements made by or on behalf of
Vida Cannabis about its business or financial objectives, position,
strategies or expectations. Such forward-looking statements may be identified
by words such as, or similar to, "intends," "anticipates," "believes,"
"expects" and "hopes" and includes, without limitation, the development of
production facilities, approval from regulatory authorities and the ability
for Vida Cannabis to obtain adequate financing to meet its business
objectives. These statements involve inherent risks and uncertainties that
could cause actual results to differ materially from those indicated. The
statements in this announcement do not guarantee future performance. Vida
Cannabis does not undertake any obligation to update any information provided
in this announcement. In Canada, Vida Cannabis (Canada) Ltd., a wholly owned
subsidiary of Vida Cannabis, must obtain approval from Health Canada in order
to operate as a licensed commercial producer under theMarihuana for Medical
Purposes Regulations
. Vida Cannabis makes no representations or warranties that it will receive
Health Canada approval.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Vida Cannabis Corp. via Globenewswire

HUG#1781771

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.